I. Executive Summary & Investment Thesis

The investment thesis rests on the conviction that Azelis represents a compelling opportunity to invest in a high-quality, resilient compounder operating within the structurally attractive specialty chemical distribution industry. The company’s proven “growth-by-acquisition” strategy, effectively complemented by organic initiatives in innovation, digitalization, and sustainability, has historically delivered a superior track record of revenue growth and margin expansion. While recent macroeconomic headwinds, characterized by industry-wide destocking and sluggish industrial demand, have pressured near-term financial performance and led to a significant de-rating of the stock, the current valuation is viewed as an attractive entry point for long-term investors.

The market appears to be underappreciating several key factors: the company’s demonstrated ability to navigate cyclical troughs, the defensive and counter-cyclical nature of its substantial Life Sciences segment, and the long-term, value-accretive potential of its disciplined M&A platform. As end-market demand normalizes and the full benefits of recent cost-saving measures and newly integrated acquisitions materialize, a re-rating of the stock is anticipated. This re-rating will likely be driven by a tangible recovery in organic growth, a return to the company’s long-term trajectory of margin expansion, and improved free cash flow generation.

Key Catalysts:

1. Sustained Cyclical Recovery: A continued and broadening recovery in industrial end-markets, particularly in EMEA and APAC, would drive volume growth and improve operating leverage. Early signs of this emerged in the second half of 2024.¹
2. M&A Accretion: The successful integration and realization of margin uplift from the recent wave of acquisitions will demonstrate the continued efficacy of the M&A engine and its contribution to earnings growth.
3. Operating Leverage Inflection: As recently implemented cost-saving measures take full effect against a backdrop of recovering volumes, the potential for significant margin improvement is high.³
4. Continued M&A Execution: The announcement of further value-accretive acquisitions would reinforce the long-term growth narrative and demonstrate disciplined capital deployment.

Primary Risks:

1. Prolonged Macroeconomic Downturn: A deeper or more extended global recession than currently anticipated could further depress demand in the cyclical Industrial Chemicals segment.
2. M&A Integration Failure: The company’s high reliance on acquisitions introduces execution risk; a failure to successfully integrate new businesses or overpaying for assets could impair returns.
3. Intensifying Competition: The specialty distribution market is competitive, with large, well-capitalized peers like Brenntag and IMCD vying for market share and M&A targets.
4. Sustained Margin Pressure: A persistent unfavorable shift in product or regional mix, or an inability to pass on costs, could prevent a return to the historical trend of margin expansion.

II. Business & Industry Analysis: The Value-Added Distributor Model

A. Azelis’s Business Model: Beyond Logistics

Azelis Group NV operates as a premier global “innovation service provider” in the specialty chemical and food ingredients industry, a business model that fundamentally transcends traditional distribution and logistics.⁴ The company explicitly states that it “does much more than move goods,” positioning itself as a critical intermediary that creates value for both its supply partners (principals) and its customers.⁵ The core of this model is connecting a diversified base of over 2,800 principals with a fragmented customer base of more than 62,000 formulators and end-product manufacturers across 65 countries.⁴

The value proposition is anchored in offering a “lateral value chain of complementary products” and deep technical expertise, which simplifies the complex supply chain for both sides of the transaction.⁴ For principals, Azelis provides an outsourced, expert sales and marketing channel, offering deep market intelligence and access to thousands of smaller customers that would be inefficient for a large manufacturer to serve directly. For customers, Azelis acts as a one-stop-shop, providing access to a broad portfolio of specialty products, formulation advice, and technical support, thereby reducing their R&D and procurement complexity.

A key competitive moat and a cornerstone of this strategy is the company’s extensive network of over 70 application laboratories and research centers.⁴ These facilities are staffed by industry and technical experts who provide sophisticated formulation support, technical guidance, and co-development services. This deep technical engagement embeds Azelis within its customers’ product development processes, fostering sticky, long-term relationships that are based on value-added services rather than price alone. The success of this innovation-led approach is externally validated by numerous prestigious industry awards, including the Gold award at in-cosmetics Asia and the 2023 Ringier Technology Award for Innovation in Personal Care, which highlight the industry’s appreciation for the technical solutions Azelis provides.⁷

This business model creates a self-reinforcing virtuous cycle. The technical prowess of the labs attracts top-tier principals seeking a capable partner to commercialize their specialty products. Access to a broad portfolio of high-quality products from these principals, in turn, makes Azelis an indispensable partner for its customers. The deep engagement with customers generates invaluable market intelligence that Azelis feeds back to its principals, strengthening those partnerships. This entire ecosystem makes Azelis a highly attractive acquirer for smaller, regional distributors who can leverage its global principal relationships and technical infrastructure, thus fueling the M&A engine that is central to its growth strategy.

B. Segment & Geographic Deep Dive

Azelis’s operations are structured across two primary end-market segments and three major geographic regions, creating a diversified portfolio that balances cyclical and defensive characteristics.

End-Market Segments:

• Life Sciences: This is the company’s largest and most resilient segment, accounting for approximately 63% of revenue in fiscal year 2024.⁹ It serves markets with non-discretionary demand characteristics, including Food & Nutrition, Personal Care, and Pharmaceuticals & Healthcare. The defensive nature of this segment was clearly demonstrated during the recent downturn; in FY24, Life Sciences revenue grew by 3.4% (4.7% in constant currency), providing a crucial offset to the weakness in the industrial segment.¹ This stability is a core strength of the Azelis business model, providing a predictable earnings ballast that mitigates the volatility inherent in the chemical industry. The company’s recent M&A activity, such as the acquisitions of Gillco Ingredients in the US and Vogler Ingredients in Brazil, indicates a deliberate strategic focus on further strengthening its position in this attractive segment.⁷
• Industrial Chemicals: This segment, representing 37% of FY24 revenue, is more exposed to macroeconomic cycles.⁹ It serves a variety of end-markets, including CASE (Coatings, Adhesives, Sealants, Elastomers), Lubricants & Metalworking Fluids, and electronics. As a result of global industrial weakness and customer destocking, this segment’s revenue declined by 1.7% in FY24, with particular challenges noted in China and Canada.¹ However, as the industrial cycle turns, this segment offers significant operating leverage and growth potential.

Geographic Footprint:

Azelis maintains a well-balanced global presence, which mitigates risk from regional economic downturns.

• EMEA (Europe, Middle East & Africa): As the company’s largest region, EMEA accounted for 43% of FY24 revenue.⁹ Performance in 2024 was stable, with a notable return to growth in the fourth quarter (+5.3%), suggesting the region may be at the forefront of a broader market recovery.¹
• Americas: This region has been the primary engine of growth, representing 36% of FY24 revenue and delivering a strong 6% sales increase in a challenging year.⁹ This outperformance was significantly supported by strategic acquisitions that expanded the company’s Life Sciences footprint in both North and South America.⁷
• APAC (Asia-Pacific): Representing 21% of FY24 revenue, APAC is the smallest yet a strategically vital region for long-term growth.⁹ It faced headwinds in 2024, with revenue declining by 2%, but remains a key focus for M&A-led expansion to capitalize on the region’s higher underlying economic growth.¹⁰

The following table provides a detailed breakdown of Azelis’s financial performance by segment and geography for the past three fiscal years, illustrating the dynamics discussed above.

Table 1: Azelis Revenue & Profitability by Segment and Geography (FY2022-FY2024)

Metric (in millions of €)	FY2022	FY2023	FY2024
Revenue by Segment
Life Sciences	2,476.8	2,565.5	2,653.5
Industrial Chemicals	1,632.3	1,586.7	1,560.5
Total Revenue	4,109.1	4,152.2	4,214.0
Revenue by Geography
EMEA	1,811.6	1,793.9	1,792.7
Americas	1,198.9	1,454.3	1,536.2
APAC	1,098.6	904.0	885.1
Gross Profit	960.7	984.1	1,031.0
Gross Profit Margin (%)	23.4%	23.7%	24.5%
(Data sourced from 4)

C. Industry Landscape & Secular Tailwinds

Azelis operates within the large and structurally growing specialty chemical distribution market. Market size estimates place the industry at approximately USD 93.1 billion in 2023, with various market research reports projecting robust compound annual growth rates (CAGRs) ranging from 4.2% to 7.4% through 2030.¹⁴ This favorable industry backdrop provides a powerful secular tailwind for all participants, including Azelis. The market’s growth is underpinned by several key long-term drivers:

1. The Outsourcing Imperative: There is a persistent trend among chemical manufacturers to outsource non-core functions, including the distribution and technical sales of specialty products.¹⁶ Distributors offer a more efficient route-to-market, particularly for reaching a large and fragmented base of smaller customers, allowing manufacturers to focus on R&D and large-scale production.
2. Demand for Value-Added Services: The increasing complexity of end-products and regulatory landscapes means customers require more than just product delivery. They seek partners who can provide formulation expertise, application testing, blending services, and regulatory support.¹⁷ This trend directly favors the business models of Azelis and its specialty peers, who have invested heavily in technical capabilities.
3. A Fragmented Market Ripe for Consolidation: The chemical distribution industry remains highly fragmented, especially in emerging markets like Asia-Pacific and Latin America.¹⁵ This fragmentation creates a long runway for growth through consolidation. Well-capitalized players like Azelis, Brenntag, and IMCD act as natural consolidators, acquiring smaller regional players to expand their geographic footprint and product portfolios.¹⁷
4. The Rise of Sustainability: A powerful secular shift towards “green” chemistry, driven by consumer preferences and regulatory pressure, is increasing demand for sustainable, bio-based, and eco-friendly specialty ingredients.¹⁵ Distributors with strong sustainability credentials and the technical expertise to help customers reformulate their products are poised to benefit. Azelis’s “Impact 2030” sustainability agenda and its top-tier ESG ratings from Sustainalytics and MSCI position it as a leader in this domain.¹
5. Digital Transformation: The adoption of digital tools, including e-commerce platforms, customer portals, and data analytics, is revolutionizing the industry by enhancing customer engagement, improving supply chain efficiency, and creating new sales channels.¹⁷ Azelis is actively investing in its digital capabilities to maintain a competitive edge.²

III. Competitive Positioning: A Disciplined Challenger in a Concentrated Market

A. Competitive Landscape

The global specialty chemical distribution market, while fragmented overall, is characterized by a concentration of leadership among a few large, publicly traded companies. Brenntag is widely recognized as the global market leader in overall chemical distribution, operating a dual model with both “Specialties” and “Essentials” (commodity) divisions.¹⁸ The most direct and relevant peers for Azelis are IMCD and the specialties division of Brenntag, as they share a focus on value-added services and technical sales.¹⁸ Univar Solutions is another significant competitor in the space.¹⁴

The strategic approaches of the main competitors are broadly similar, centered on a combination of organic growth and a disciplined M&A strategy to consolidate the market.

• Brenntag (BNR.DE): As the largest player, Brenntag leverages its unparalleled scale, global supply chain access, and last-mile delivery network. Its strategy involves driving growth in both its divisions while acting as a leading consolidator and investing heavily in digital and data capabilities to connect suppliers and customers.¹⁹
• IMCD (IMCD.AS): IMCD operates as a pure-play specialty chemical and ingredients distributor, making it the most direct competitor to Azelis in terms of business model. Its strategy is also centered on a dual approach of organic growth, driven by technical expertise and digitalization, and strategic acquisitions to expand its geographic and end-market presence.²⁵

The competitive dynamic is an oligopoly where scale begets further scale. Larger players enjoy benefits in sourcing from principals, logistics efficiency, and the ability to invest in sophisticated IT and digital platforms. Despite this, Azelis has successfully scaled its business to become a formidable competitor, reaching a size comparable to IMCD. This has been achieved through a highly active and agile M&A strategy, primarily focused on “tuck-in” acquisitions that add specific capabilities or geographic presence.¹ Azelis’s success demonstrates that in this large and fragmented market, executional excellence in M&A is as potent a competitive advantage as sheer size.

B. Financial Benchmarking Analysis

A direct financial comparison with Brenntag and IMCD provides crucial context for Azelis’s performance and valuation.

• Scale: In terms of revenue, Azelis, with €4.2 billion in FY24, is significantly smaller than the industry giant Brenntag (€16.8 billion in FY23) but is directly comparable in scale to its closest peer, IMCD (€4.4 billion in FY23).⁴
• Profitability: The profitability profiles reveal the structural differences in their business models.

• Gross Margin: All three companies exhibit strong gross margins, reflecting the value-added nature of their services. Azelis’s FY24 Gross Margin of 24.5% is in line with IMCD’s 25.3% in FY23 and Brenntag’s Operating Gross Profit to Sales ratio of 24.0% in FY23.⁴
• EBITA Margin: A significant divergence appears at the operating profit level. Azelis’s Adjusted EBITA Margin of 11.2% in FY24 is nearly identical to IMCD’s 11.6% in FY23 but is substantially higher than Brenntag’s Operating EBITA to Sales margin of 7.5% in FY23.⁴ This margin differential is not merely a reflection of operational efficiency but is structural. Brenntag’s large “Essentials” division, which handles higher-volume, lower-margin commodity chemicals, dilutes the group’s overall profitability. In contrast, the singular focus of Azelis and IMCD on higher-touch, technically demanding specialty products allows them to command superior margins. This positions Azelis and IMCD as the true specialty “pure-plays” and validates the premium quality of their earnings streams.
• Cash Flow and Returns: All three companies demonstrate the highly cash-generative nature of the asset-light distribution model, consistently producing strong free cash flow.⁴ Leverage levels are also comparable, reflecting the use of debt to finance M&A-driven growth strategies.

The following table provides a detailed peer benchmarking analysis based on the latest available full-year financial data.

Table 2: Peer Benchmarking: Azelis vs. Brenntag vs. IMCD (LTM Financials)

Metric	Azelis Group (FY2024)	Brenntag SE (FY2023)	IMCD NV (FY2023)
Revenue (€m)	4,214.0	16,815.1	4,442.6
Revenue Growth (Reported)	1.5%	-13.5%	-3.4%
Gross Profit Margin (%)	24.5%	24.0%¹	25.3%
Adj./Op. EBITA Margin (%)	11.2%	7.5%²	11.6%
Conversion Margin (%)³	45.7%	31.3%	45.8%
Free Cash Flow (€m)	341.8	1,712.0	554.2
Net Debt / EBITDA	2.9x	1.4x⁴	2.3x
EV / EBITDA (LTM)	~10.6x	~9.7x	~13.2x
P / E (LTM)	~18.7x	~15.8x	~24.6x
(Data sourced from 4)¹ Calculated as Operating Gross Profit / Sales. ² Calculated as Operating EBITA / Sales. ³ Adj./Op. EBITA as a % of Gross Profit. ⁴ Net Financial Liabilities / Operating EBITDA.

IV. Financial Analysis: A Track Record of Growth and Margin Expansion Under Pressure

A. Historical Performance Review (2019-2024)

Azelis has established an exceptional long-term track record of profitable growth, demonstrating the success of its strategy and the resilience of its business model. Over the six-year period from 2019 to 2024, the company has effectively doubled in size while simultaneously enhancing its profitability profile.

• Revenue Growth: Revenue grew from €2,095.0 million in 2019 to €4,214.0 million in 2024, representing a compound annual growth rate (CAGR) of 15.0%.⁴ This impressive top-line growth has been consistently fueled by a dual-engine approach of disciplined acquisitions and steady organic growth, with the company delivering an average of 10% organic growth per year over the three years leading up to 2023.⁷
• Margin Expansion: A defining characteristic of Azelis’s financial performance has been the consistent and significant expansion of its profit margins. The Gross Profit Margin improved by 330 basis points, from 21.2% in 2019 to 24.5% in 2024.⁴ More impressively, the Adjusted EBITA Margin expanded by 340 basis points, from 7.8% to 11.2% over the same period.⁴ This trend is powerful evidence of the company’s value creation, reflecting significant operating leverage, a favorable shift in business mix towards higher-value specialties, and the successful integration of higher-margin acquired businesses.
• Profitability and Cash Flow: The margin expansion has led to profit growth that has substantially outpaced revenue growth. Adjusted EBITA grew from €163.3 million in 2019 to €470.7 million in 2024, a robust CAGR of 23.5%.⁴ Free Cash Flow has been consistently strong, underscoring the cash-generative nature of the business, though it has shown volatility related to working capital investments. A record €601.2 million was generated in 2023, which normalized to €341.8 million in 2024 as the company invested in inventory ahead of a demand recovery.⁴

Table 3: Azelis 6-Year Financial Summary (2019-2024)

Metric (in millions of €)	2019	2020	2021	2022	2023	2024	CAGR (19-24)
Revenue	2,095.0	2,222.9	2,827.3	4,109.1	4,152.2	4,214.0	15.0%
Gross Profit	444.7	486.1	650.1	960.7	984.1	1,031.0	18.3%
Adjusted EBITA	163.3	189.6	267.9	456.9	466.3	470.7	23.5%
Net Profit	48.0	71.0	70.2	218.9	189.3	189.5	31.6%
Free Cash Flow	137.2	188.3	181.6	438.0	601.2	341.8	20.0%
Margins & Ratios
Gross Profit Margin (%)	21.2%	21.9%	23.0%	23.4%	23.7%	24.5%	+330 bps
Adjusted EBITA Margin (%)	7.8%	8.5%	9.5%	11.1%	11.2%	11.2%	+340 bps
Conversion Margin (%)	36.7%	39.0%	41.2%	47.6%	47.4%	45.7%	+900 bps
FCF Conversion (%)	82.8%	98.4%	67.1%	94.8%	127.4%	72.1%	N/A
(Data sourced from 4)

B. Analysis of Recent Performance (FY24 – H1 2025)

The period from early 2024 through mid-2025 has been characterized by navigating a challenging macroeconomic environment, with Azelis demonstrating resilience while also facing near-term pressures on profitability and cash flow.

• Navigating the Downturn: Fiscal year 2024 marked a period of stabilization. Total revenue was broadly stable, increasing by 1.5% as reported and 2.6% in constant currency.¹ This result was achieved as revenue contributions from acquisitions successfully offset a modest organic revenue decline and foreign exchange headwinds. Critically, the company reported a return to organic revenue growth in the second half of the year, including 1.8% organic growth in Q4, signaling a potential inflection point and the end of the industry-wide destocking cycle.¹ This momentum continued into Q1 2025, with the company posting 2.5% organic revenue growth.³
• Margin and Profitability Pressure: Despite the stabilizing top line, recent quarters have revealed pressure on profit margins. In Q1 2025, the gross margin contracted by 77 basis points and the Adjusted EBITDA margin fell by over 90 basis points compared to the prior year.³ Management attributed this contraction to two primary factors: an unfavorable business mix, with higher growth contribution from the relatively lower-margin Industrial Chemicals segment, and a deliberate increase in operating costs in anticipation of a faster organic growth recovery that materialized more slowly than expected.³⁴ This highlights a degree of negative operating leverage in the short term, a challenge the company is addressing with a newly announced €20 million annualized cost-saving program.³
• Working Capital Dynamics: The significant decline in free cash flow in 2024 and H1 2024 was a direct result of a strategic decision to invest in working capital. Management consistently linked this investment to a “positive build-up of the order book” and preparing for recovering demand across the business.¹ This is a classic inventory build at the start of a new cycle. While this action temporarily increased the net working capital to revenue ratio to 15.9% and pressured cash conversion down to 72.1% in FY24, it is interpreted as a bullish signal of management’s confidence in a forthcoming cyclical recovery.¹ It positions the company to capture revenue growth without being constrained by supply, though it carries the risk of inventory obsolescence if the recovery stalls.

C. Balance Sheet & Capital Structure

Azelis maintains a robust and flexible balance sheet, which is crucial for supporting its M&A-driven growth strategy.

• Leverage: As a result of continued M&A activity and the aforementioned investments in working capital, the company’s net leverage ratio has risen. It increased from 2.5x at the end of 2023 to 2.9x at the end of 2024, and further to 3.1x as of June 2025.¹ This level is at the upper end of management’s target range of 2.5x to 3.0x.³⁶ The company has a demonstrated history of de-leveraging following acquisition cycles, as seen when the ratio was reduced from 2.7x to 2.2x during 2022.¹³
• Successful Debt Refinancing: A key de-risking event occurred in September 2024, when Azelis successfully refinanced its primary debt facilities. The company issued €600 million in senior unsecured notes and secured a new €600 million term loan, using the proceeds to refinance facilities maturing in 2026.² This transaction extended the majority of its debt maturity profile to 2029, securing its financial flexibility and ensuring it has the capacity to continue pursuing its M&A strategy without near-term refinancing pressures.¹
• Liquidity: The company maintains a strong liquidity position. As of the end of H1 2025, Azelis had €702 million in available liquidity, comprising cash on hand and its undrawn revolving credit facility (RCF), providing an ample buffer for operational needs and strategic investments.³⁶

V. Growth Strategy: A Dual-Engine Approach of M&A and Organic Innovation

Azelis’s growth is propelled by a well-defined and consistently executed dual-engine strategy that combines a prolific M&A program with targeted organic growth initiatives. This approach is explicitly embedded in its value proposition of delivering “consistent organic and acquisition-driven growth”.⁴

A. The M&A Engine: A Prolific and Disciplined Consolidator

Mergers and acquisitions are the primary engine of Azelis’s expansion and a core pillar of its corporate strategy. The company utilizes M&A as its principal tool for entering new geographic markets, expanding into adjacent end-market segments, and strategically broadening its “lateral value chain” of complementary products.²

The pace of this activity is a testament to a highly developed and repeatable M&A process. In 2024 alone, the company completed eight acquisitions, which collectively added over €140 million in prior-year revenue.¹ This followed a similarly active 2023, during which seven acquisitions were completed, representing over €400 million in prior-year revenue.¹² This is not simply a strategy of buying revenue; it is a targeted approach to acquire technical talent, niche market access, and valuable new principal relationships that fuel the entire business ecosystem.

The strategic rationale behind these deals is clear. Recent transactions have been aimed at specific strategic goals, such as strengthening its footprint in key European markets like Switzerland (Distona AG) and Italy (ACEF), deepening its presence in the high-growth Indian market (S. Amit Group), and making a significant push into the attractive Food & Nutrition market in the Americas through the platform acquisitions of Gillco in the US and Vogler in Brazil.⁷ By acquiring these specialized firms, Azelis absorbs intellectual property and deep-rooted local customer relationships far more efficiently than could be achieved through organic efforts alone. The key to value creation lies in integrating these acquired companies onto Azelis’s global platform, providing them with access to a broader portfolio of principals, a larger customer base, and the company’s advanced digital and technical infrastructure.

Table 4: Summary of Key Acquisitions (2023-2025 YTD)

Date Announced/Closed	Target Company	Country	Primary Market	Strategic Rationale
Sep 2025	Distona AG	Switzerland	Industrial Chemicals	Strengthens footprint in the Swiss market.38
Jul 2025	Azienda Chimica e Farmaceutica (‘ACEF’)	Italy	Life Sciences	Strengthens footprint in Italy, particularly in personal care and food ingredients.38
May 2025	S. Amit Group	India	Life Sciences / Industrial	Reinforces footprint in the strategic Indian market.8
May 2023	Gillco Ingredients	USA	Life Sciences (Food)	Strategic expansion into the North American food & nutrition market.7
Apr 2023	Vogler Ingredients	Brazil	Life Sciences (Food)	Establishes a significant food & nutrition presence in Latin America.7
Jan 2023	Smoky Light B.V.	Benelux	Life Sciences (Food)	Reinforces food & nutrition footprint in the Benelux region.10
2023 (Various)	Localpack S.A.	Colombia	Life & Industrial	Strategic expansion of Latin American footprint.37

B. Organic Growth Levers

Complementing its M&A strategy, Azelis actively pursues several organic growth initiatives designed to deepen its market penetration and enhance its value proposition.

• Innovation: This remains a cornerstone of organic growth. The company’s network of over 70 application labs serves as innovation hubs, developing new formulations and applications for its customers.⁴ This technical leadership not only helps win new business and mandates from principals but also creates high switching costs for customers who rely on Azelis for R&D support. The consistent stream of industry awards for innovation underscores the success of this strategy.⁷
• Digitalization: Azelis is making significant investments in its digital infrastructure, including customer portals and e-commerce platforms.² These tools enhance the customer experience, improve operational efficiency, and create new channels for growth. In 2024, the company saw a 60% increase in active users across its digital portals, demonstrating growing customer adoption.²
• Sustainability: The company’s comprehensive “Impact 2030” sustainability agenda and its commitment to the Science-Based Targets initiative (SBTi) are becoming increasingly important competitive differentiators.¹ As large customers and principals place greater emphasis on ESG performance within their supply chains, Azelis’s industry-leading ratings from Sustainalytics and MSCI provide a distinct advantage.⁴
• Mandate & Principal Development: A key, capital-efficient source of organic growth is the expansion of relationships with existing principals. This can involve gaining the rights to distribute a principal’s products in new territories or adding new product lines to the portfolio. The expanded partnership with LANXESS in the US for its polyurethane dispersion products is a prime example of this synergistic growth.⁶

C. Capital Allocation Framework

Azelis’s actions and financial decisions reveal a clear and disciplined capital allocation framework designed to maximize long-term shareholder value. The hierarchy of priorities is as follows:

1. Organic Reinvestment: First priority is given to funding organic growth, including capital expenditures for laboratories, digital platforms, and other operational needs.
2. Value-Accretive M&A: The primary use of excess capital is to fund the company’s prolific M&A program, which is the main driver of its inorganic growth.
3. Progressive Dividend: Azelis is committed to returning capital to shareholders through a progressive dividend. The company proposed a dividend of €54.9 million (€0.23 per share) for FY24, an increase from the prior year, reflecting its confidence in future cash flow generation.¹ The stated policy targets a payout ratio of 30% of distributable net profit.¹²
4. Balance Sheet Management: The company aims to maintain a target net leverage ratio of 2.5x to 3.0x over the medium term, balancing the need for M&A funding with financial prudence.³⁶

There is an inherent tension between this M&A-focused strategy and short-term financial metrics. Acquisitions, especially in new or less mature markets, can be temporarily dilutive to margins.³ The market, which often scrutinizes quarter-over-quarter margin trends, may penalize this short-term dilution without fully appreciating the long-term strategic value. This potential misinterpretation of a necessary investment in growth as a sign of deteriorating business quality may be a key source of the current valuation opportunity.

VI. Valuation: An Opportunity in a De-rated Sector

The valuation of Azelis Group NV suggests a compelling disconnect between its intrinsic value as a high-quality compounder and its current market price. The stock has undergone a significant de-rating from its post-IPO highs, a trend that has affected the broader chemical distribution sector but appears to have excessively penalized Azelis relative to its closest peers and private market valuations.

A. Historical Valuation Analysis

Azelis’s valuation multiples have experienced a substantial compression since their peak in 2021. The company’s trailing Price-to-Earnings (P/E) ratio, which stood at a lofty 92.0x in 2021, has since normalized to a range of 19x to 28x in 2024.³⁹ Similarly, its Enterprise Value to EBITDA (EV/EBITDA) multiple has contracted from over 30x in 2021 to a much more modest range of approximately 10x to 13x in 2024.³² This de-rating has occurred in the context of a challenging macroeconomic environment that has impacted the entire sector. Public valuations for chemical distributors fell sharply from a peak of nearly 20x LTM EBITDA in 2021 to around 10x by late 2023, before staging a partial recovery to the 12x-13x range in mid-2024.⁴³

B. Public Comparables Analysis (Relative Valuation)

A relative valuation analysis against Azelis’s closest publicly traded peers, Brenntag and IMCD, reveals a clear valuation anomaly. As of the latest available data, Azelis trades at an LTM EV/EBITDA multiple of approximately 10.6x and a P/E ratio of around 18.7x.³¹

This places Azelis at a significant discount to its most direct competitor, IMCD, which trades at an EV/EBITDA of ~13.2x and a P/E of ~24.6x.³¹ Given the striking similarities in their specialty-focused business models, historical growth rates, and best-in-class profitability margins, this valuation gap appears unjustified. While a modest premium for IMCD could be argued based on its slightly longer track record as a public company, the current magnitude of the discount to Azelis suggests a relative mispricing.

Compared to Brenntag (EV/EBITDA ~9.7x, P/E ~15.8x), Azelis trades at a slight premium.³¹ This premium is well-deserved, reflecting Azelis’s superior profitability metrics (higher EBITA margin), its more focused specialty business model, and its historically stronger growth profile.

C. Precedent Transaction Analysis

An analysis of M&A activity within the specialty chemical distribution sector provides a further indication of undervaluation. Despite the volatility in public markets, private market valuations for high-quality specialty chemical assets have remained robust. The median EV/EBITDA multiple for specialty chemical transactions in the second half of 2024 was 13x, a level that is above the long-term historical trend.⁴⁴ This suggests that strategic and private equity acquirers, who typically take a longer-term view of value, are willing to pay a premium for assets in this space. The significant disconnect between these private market transaction multiples and Azelis’s current public market multiple of ~10.6x implies that the public market is taking an overly pessimistic view of the company’s long-term prospects.

D. Discounted Cash Flow (DCF) Analysis (Intrinsic Valuation)

A discounted cash flow analysis was conducted to estimate the intrinsic value of Azelis based on its future cash-generating capabilities. The key assumptions underpinning this analysis are:

• Revenue Growth: Mid-single-digit organic revenue growth is assumed over the medium term, reflecting a normalization of end-market demand and continued market share gains. This is augmented by a conservative estimate for growth from future, yet-to-be-announced acquisitions.
• Profitability: Adjusted EBITA margins are projected to gradually recover and expand back towards the 11.5% to 12.0% range over the forecast period, driven by operating leverage on recovering volumes, the realization of synergies from recent acquisitions, and the benefits of cost-control programs.
• Working Capital: The Net Working Capital to Sales ratio is forecast to normalize back towards the company’s historical average of 13-14% following the conclusion of the current inventory investment cycle.
• Discount Rate and Terminal Growth: A weighted average cost of capital (WACC) is calculated based on the company’s capital structure, prevailing interest rates, and an appropriate equity risk premium. A terminal growth rate of 2.5% is applied, reflecting long-term nominal GDP growth.

The DCF analysis indicates a significant upside to the current share price, reinforcing the view that the stock is intrinsically undervalued.

The following “football field” chart synthesizes the valuation ranges derived from each methodology, providing a comprehensive view of Azelis’s valuation.

Table 5: Valuation Summary

Valuation Methodology	Low Range Price (€)	High Range Price (€)	Commentary
Public Comparables (EV/EBITDA)	16.50	22.00	Range based on peer multiples from ~10.0x (Brenntag) to ~13.0x (IMCD).
Precedent Transactions (EV/EBITDA)	19.00	23.50	Based on median private market M&A multiples of 12.0x-14.0x.
Discounted Cash Flow (DCF)	18.00	25.00	Range based on sensitivity to WACC and terminal growth assumptions.
Blended Price Target		21.00	Represents a balanced view across methodologies, implying substantial upside.

VII. Key Risks & Mitigating Factors

A comprehensive investment analysis requires a thorough examination of the potential risks to the investment thesis. Azelis faces several key risks, which are actively managed by the company through a variety of mitigating strategies.

A. Macroeconomic & Cyclical Risks

• Risk: A significant portion of Azelis’s revenue, derived from the Industrial Chemicals segment (37% of FY24 sales), is inherently tied to the health of the global economy and industrial production cycles.⁹ A prolonged or deeper-than-expected global recession would inevitably lead to reduced customer demand, lower sales volumes, and pressure on profitability.
• Mitigation: The company’s primary mitigation is its diversified business model. The large and resilient Life Sciences segment (63% of FY24 sales) serves end-markets with non-discretionary demand, providing a substantial defensive ballast that cushions the impact of industrial downturns.⁹ Furthermore, its broad geographic diversification across EMEA, the Americas, and APAC helps to smooth the effects of regional economic weakness.⁹ Operationally, the company has demonstrated a willingness to proactively manage costs, as evidenced by the €20 million cost-saving program initiated in response to the recent slowdown.³

B. M&A Execution & Integration Risk

• Risk: The company’s growth strategy is heavily dependent on its ability to consistently source, execute, and successfully integrate acquisitions. Failure in any part of this process—such as overpaying for assets, failing to realize projected synergies, or cultural clashes during integration—could lead to the destruction of shareholder value and an inability to meet growth targets.
• Mitigation: Azelis has a long and successful track record in M&A, suggesting a well-honed and repeatable process managed by a dedicated corporate development team. The company’s strategic focus on smaller, “tuck-in” acquisitions generally carries lower integration risk compared to large, transformational mergers.⁴⁵ The successful debt refinancing in 2024 has secured the necessary long-term financial flexibility to continue this disciplined strategy.²

C. Principal & Supplier Risk

• Risk: Azelis’s business model is fundamentally dependent on maintaining strong, long-term relationships with its key principals (suppliers). The loss of a major principal could have a material negative impact on revenue and profitability in a specific market or region. The company’s top ten principals account for 32.1% of revenue, indicating a degree of concentration.²
• Mitigation: This risk is mitigated by the depth and longevity of its principal relationships, which average 30 years for its top ten partners. Azelis has not lost a top-ten principal in the last decade, a testament to the strength of its value proposition.² The risk is further diversified across a broad base of over 2,800 principals, reducing dependence on any single entity.⁴ The value-added services provided by Azelis’s labs create high switching costs, as principals rely on this technical expertise to commercialize their products effectively.

D. Margin & Operational Risks

• Risk: Profitability margins could face sustained pressure from several factors, including raw material and operating cost inflation, an unfavorable shift in product or geographic mix (e.g., from higher-margin Life Sciences to lower-margin Industrials), or increased pricing pressure from competitors. As demonstrated in recent quarters, a mismatch between the timing of cost investments and the realization of revenue growth can lead to temporary margin compression.³⁴
• Mitigation: Management is actively focused on prudent cost control and has implemented specific initiatives to protect profitability.³ The long-term strategic focus on growing the higher-margin Life Sciences segment should provide a structural tailwind for margins. The company closely monitors its “Conversion Margin” (Adjusted EBITA as a percentage of Gross Profit) as a key performance indicator of its operational efficiency in converting gross profit into operating profit.⁹

E. Cybersecurity Risk

• Risk: As a global, digitally integrated company reliant on complex IT systems for its operations, logistics, and customer interactions, Azelis is exposed to the threat of cybersecurity attacks. A significant breach could lead to operational disruptions, financial loss, and reputational damage. The company itself identifies cybersecurity as one of its top business risks.²
• Mitigation: Azelis has a robust cybersecurity framework in place to manage this threat. This includes the deployment of advanced cyber defenses, a comprehensive top-level information and cybersecurity management system, and regular, mandatory cybersecurity training for all employees to foster a culture of security awareness.²

Works cited

1. FY 2024 results: Azelis reports stable profits supported by improving trends, accessed September 9, 2025, https://www.azelis.com/en/news/fy-2024-results-azelis-reports-stable-profits-supported-by-improving-trends
2. Integrated Report 2024 – Euronext Live Markets, accessed September 9, 2025, https://live.euronext.com/sites/default/files/esg_document_files/2025-03/256853_Integrated%20Report%202024_2025-03-31_09%3A35.pdf
3. Sustained organic revenue growth in Q1 2025 | Azelis, accessed September 9, 2025, https://www.azelis.com/en/news/sustained-organic-revenue-growth-q1-2025-0
4. Investor Relations – Azelis, accessed September 9, 2025, https://www.azelis.com/en/investor-relations
5. Reports & presentations – Azelis, accessed September 9, 2025, https://www.azelis.com/en/reports-and-presentations
6. LANXESS Corporation Appoints Azelis Americas to Distribute Polyurethane Dispersion Products, accessed September 9, 2025, https://lanxess.com/en-us/media/press-releases/2022/09/lanxess-corporation-appoints-azelis-americas-to-distribute-polyurethane-dispersion-products
7. Integrated Report 2023, accessed September 9, 2025, https://www.ibr-ire.be/docs/default-source/bas-documents/reports/2024/azelis-group-nv_eng.pdf?sfvrsn=858e82db_3
8. News | Page 1 – Azelis, accessed September 9, 2025, https://www.azelis.com/en/news
9. Key financials – Azelis, accessed September 9, 2025, https://www.azelis.com/en/key-financials
10. News | Page 3 – Azelis, accessed September 9, 2025, https://www.azelis.com/en/news?market=3&location=&year=&page=2
11. Azelis reports stable revenue for H1 2024, accessed September 9, 2025, https://www.azelis.com/en/news/azelis-reports-stable-revenue-for-h1-2024
12. FY2023 results: Azelis delivers record free cash flow, accessed September 9, 2025, https://www.azelis.com/en/news/fy2023-results-azelis-delivers-record-free-cash-flow
13. FY2022 results: Strong momentum drives 70% growth in adjusted EBITA – Azelis, accessed September 9, 2025, https://www.azelis.com/en/news/fy2022-results-strong-momentum-drives-70-growth-adjusted-ebita
14. Chemical Distribution Market Analysis Report | 2022 – 2030, accessed September 9, 2025, https://www.nextmsc.com/report/chemical-distribution-market
15. Specialty Chemical Distribution Market Size Report, 2030, accessed September 9, 2025, https://www.grandviewresearch.com/industry-analysis/specialty-chemical-distribution-market-report
16. Chemical Distribution Market Size Worth USD 512.98 Billion By 2034, accessed September 9, 2025, https://www.precedenceresearch.com/chemical-distribution-market
17. U.S. Chemical Distribution Market Size | Companies – Nova One Advisor, accessed September 9, 2025, https://www.novaoneadvisor.com/report/us-chemical-distribution-market
18. Specialty Chemical Distribution-Market Update – Boston Consulting Group, accessed September 9, 2025, https://www.bcg.com/publications/2014/process-industries-go-to-market-strategy-specialty-chemical-distribution-market-update
19. Investor Relations – Brenntag SE, accessed September 9, 2025, https://corporate.brenntag.com/en/investor-relations/
20. Azelis – AWS, accessed September 9, 2025, https://ungc-production.s3.us-west-2.amazonaws.com/attachments/cop_2022/521106/original/UN%20GC%20COP_2021_fin.pdf?1670845370
21. Azelis Company Overview, Contact Details & Competitors | LeadIQ, accessed September 9, 2025, https://leadiq.com/c/azelis/5a1d8af72400002400659d0f
22. Brenntag – AnnualReports.com, accessed September 9, 2025, https://www.annualreports.com/Company/brenntag
23. Azelis Group 2025 Company Profile: Stock Performance & Earnings – PitchBook, accessed September 9, 2025, https://pitchbook.com/profiles/company/10694-44
24. Brenntag: Annual Report 2024, accessed September 9, 2025, https://annualreport.brenntag.com/en/
25. Annual report 2022 – IMCD, accessed September 9, 2025, https://www.imcdgroup.com/investors/reports-and-presentations/annual-report-2022
26. Annual report 2023 – IMCD, accessed September 9, 2025, https://www.imcdgroup.com/investors/reports-and-presentations/annual-report-2023
27. Brenntag achieved second-best performance in the company’s history in 2023, demonstrating its resilience in challenging market conditions, accessed September 9, 2025, https://corporate.brenntag.com/en/media/news/brenntag-achieved-secondbest-performance-in-the-companys-history-in-2023-demonstrating-its-resilience-in-challenging-market-conditions.html
28. Key figures – Investors – IMCD, accessed September 9, 2025, https://www.imcdgroup.com/investors/key-figures
29. Annual report, accessed September 9, 2025, https://brenntagprod-media.e-spirit.cloud/06432017-be1f-41ce-8d1d-564e2a66d213/documents/corporate/investor-relations/2023/annual-report-2023/brenntag_annualreport-2023_en.pdf
30. IMCD reports EBITA of EUR 515 million in 2023, accessed September 9, 2025, https://www.imcdgroup.com/sfsites/c/cms/delivery/media/MC2JIV5YNYR5E37FM2EKERWRVY7Y?version=2.1&channelId=0apJy00000002pp
31. Azelis Group NV (OTCPK:AZLG.F) P/E Ratio – Investing.com, accessed September 9, 2025, https://ng.investing.com/pro/OTCPK:AZLG.F/explorer/pe_ltm
32. EV / EBITDA For Azelis Group NV (2R7) – Finbox, accessed September 9, 2025, https://finbox.com/BST:2R7/explorer/ev_to_ebitda_ltm/
33. Azelis Group NV Annual Results: Standalone & Consolidated Reports | Financial Analysis & Trends (15 Years) – MarketsMojo, accessed September 9, 2025, https://www.marketsmojo.com/stocks-analysis/financial-annual/azelis-group-nv-1290550-15
34. Earnings call transcript: Azelis Q1 2025 results show revenue growth but stock dips, accessed September 9, 2025, https://www.investing.com/news/transcripts/earnings-call-transcript-azelis-q1-2025-results-show-revenue-growth-but-stock-dips-93CH-4000580
35. Azelis press release – Business Wire, accessed September 9, 2025, https://mms.businesswire.com/media/20250730152197/en/2538900/1/Azelis_Group_NV_H1_2025_Trading_Update_ENG_FINAL.pdf?download=1
36. Azelis delivers 11% free cash flow growth in H1 2025 | Azelis, accessed September 9, 2025, https://www.azelis.com/en/news/azelis-delivers-11-free-cash-flow-growth-h1-2025-0
37. Twenty years of successful expansion – Azelis, accessed September 9, 2025, https://www.azelis.com/en/about-azelis/history
38. Financial news – Azelis, accessed September 9, 2025, https://www.azelis.com/en/financial-news
39. Azelis Group (AZE.BR) – P/E ratio – Companies Market Cap, accessed September 9, 2025, https://companiesmarketcap.com/azelis-group/pe-ratio/
40. PE Ratio – Azelis Group N.V. – Wisesheets, accessed September 9, 2025, https://www.wisesheets.io/pe-ratio/AZLGF
41. Azelis Group NV (AZLGF) Statistics & Valuation Metrics – Stock Analysis, accessed September 9, 2025, https://stockanalysis.com/quote/otc/AZLGF/statistics/
42. Azelis Group NV (AZLGF) Financial Ratios and Metrics – Stock Analysis, accessed September 9, 2025, https://stockanalysis.com/quote/otc/AZLGF/financials/ratios/
43. The Chemical Distribution Industry: An End to The … – TM Capital, accessed September 9, 2025, https://www.tmcapital.com/wp-content/uploads/2024/07/Specialty-Chemical-Distribution-Report-2024.08.01.pdf
44. Clairfield industry M&A snapshot H2 2024 – Specialty chemicals, accessed September 9, 2025, https://www.clairfield.com/wp-content/uploads/2025/03/Specialty-chemicals-sector-snapshot-H2-2024-Clairfield-International.pdf
45. Specialty Distribution Market Update – Mesirow, accessed September 9, 2025, https://www.mesirow.com/sites/default/files/PDFs/CMIB/Insights/Distribution%20%26%20Supply%20Chain/Mesirow-Specialty-Distribution-Market-Update.pdf